Pharmacokinetics of Rofecoxib

@article{Davies2003PharmacokineticsOR,
  title={Pharmacokinetics of Rofecoxib},
  author={Neal M. Davies and Xiao Wei Teng and Neil M. Skjodt},
  journal={Clinical Pharmacokinetics},
  year={2003},
  volume={42},
  pages={545-556}
}
Rofecoxib is a commonly used specific cyclo-oxygenase-2 (COX-2) inhibitor. Rofecoxib has high bioavailability, poor aqueous solubility, an elimination half-life suitable for daily administration and a volume of distribution approximating body mass. Species-specific, predominantly hepatic, metabolism occurs, with novel enterohepatic circulation in rats and O-glucuronidation by uridine diphosphate-glucuronosyl transferase (UGT) 2B7 and 2B15 in human liver microsomes. Discrepancies in studies of… 
Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib
TLDR
The renal adverse effects of etoricoxib appear to be similar to those of other NSAIDs, and the cardiovascular adverseeffects of this selective COX-2 inhibitor require further clinical scrutiny.
IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
TLDR
It was determined that CYP2C9 plays a relatively minor role in the overall clearance of sulindac, naproxen, ketoprofen, diclofenac, rofecoxib, and etoricoxib and CYP1C9 genotype would have no clinically meaningful impact on the pharmacokinetics of these drugs.
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
  • N. Davies, F. Jamali
  • Medicine, Biology
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2004
TLDR
The use of highly COX-2 selective NSAIDs without the use of a suitableCOX-1 inhibitor, (e.g., low dose aspirin) may be best avoided and may be particularly relevant to the chronic use of these drugs.
Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects
TLDR
It is indicated that esomeprazole can be used in combination with NSAIDs without the risk of a pharmacokinetic interaction and does not affect the pharmacokinetics of naproxen or rofecoxib.
Covalent Binding of Rofecoxib, but Not Other Cyclooxygenase-2 Inhibitors, to Allysine Aldehyde in Elastin of Human Aorta
TLDR
The results suggest that rofecoxib, but not other COX-2 inhibitors, is capable of covalently binding to the aldehyde group of allysine in human elastin.
Effect of inflammation on kidney function and pharmacokinetics of COX‐2 selective nonsteroidal anti‐inflammatory drugs rofecoxib and meloxicam
TLDR
It is concluded that inflammation does not exacerbate the adverse effect of NSAIDs on kidney under healthy and inflammatory conditions, and the ratios of the kidney:plasma concentrations were not significantly altered by inflammation following either drug.
Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
TLDR
Although there are still insufficient data concerning certain important adverse effects of rofecoxib, this drug is becoming an important alternative in the therapy of osteoarthritis, especially in high-risk patients, and clinicians need to weigh up the benefits and risks on a case-by-base basis.
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
TLDR
The current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes is summarized and no other drugs have an evidence base that is sufficient to justify prospective testing at present, although some warrant further evaluation.
Bioequivalence Study and Pharmacokinetic Evaluation of Two Brands of Rofecoxib 25 mg Tablets in a Lebanese Population
TLDR
This was an open-label, randomized, double blind, single dose, two-way, non-replicated cross over design, with 19 days wash-out, and the extraction procedure and HPLC analysis were adapted from previously published methods.
...
1
2
3
...

References

SHOWING 1-10 OF 52 REFERENCES
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
TLDR
It is indicated that rofecoxib is a potent and specific inhibitor of COX-2 in humans even at doses more than tenfold higher than those associated with efficacy in patients with osteoarthritis.
The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
TLDR
Rofecoxib underwent extensive metabolism in humans, and very little parent drug was recovered unchanged in urine (<1%).
The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
  • R. Halpin, L. Geer, K. Vyas
  • Medicine, Biology
    Drug metabolism and disposition: the biological fate of chemicals
  • 2000
TLDR
Radioactivity distributed rapidly to tissues, with the highest concentrations of the i.v. dose observed in most tissues by 5 min and by 30 min in liver, skin, fat, prostate, and bladder.
Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptives in Healthy Female Volunteers
TLDR
The addition of rofecoxib to the oral contraceptive was not associated with any clinically important changes in EE or NET pharmacokinetics and thus would not be anticipated to influence the efficacy of this contraceptive regimen.
Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers
TLDR
Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin, and no treatment‐related pattern was apparent.
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
TLDR
The data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition ofcox-1.
Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.
  • T. Baillie, R. Halpin, K. Vyas
  • Medicine, Chemistry
    Drug metabolism and disposition: the biological fate of chemicals
  • 2001
TLDR
Treatment of rats with [5-(18)O]5-hydroxyrofecoxib, followed by liquid chromatography-tandem mass spectrometry analyses of plasma samples, confirmed that 5-hydroxylation of roficoxib undergoes metabolism to the parent drug, yielding [1-2-3-4-O], [2-2)O], and unlabeled rofecxib.
Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients
TLDR
It was concluded that rofecoxib at doses of 12.5, 25, and 50 mg once daily has no effect on the plasma concentrations or renal clearance of methotrexate in rheumatoid arthritis patients.
Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet
TLDR
To determine the effects of COX-2 inhibition on glomerular filtration rate and serum and urine electrolyte balance, rofecoxib was administered to elderly patients who were receiving a sodium-restricted diet, which enhanced renal dependence on prostaglandin production.
Inhibition of COX-2 counteracts the effects of diuretics in rats.
TLDR
Findings suggest that COX-2-derived prostanoids are of major relevance in modulating the renal effects of diuretics and might be valuable drugs to treat salt and water wasting during Bartter and Gitelman diseases.
...
1
2
3
4
5
...